NCT05939414招募中3 期
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 450
- 试验地点
- 192
- 主要终点
- Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
详细描述
All participants will be assessed for eligibility and will undergo baseline disease assessments including a mandatory gallium (68Ga) gozetotide (also known as [68Ga]Ga-PSMA-11) or piflufolastat (18F) ( also known as[18F]DCFPyL) PET/CT scan and CI (i.e., CT/MRI and bone scans).
Piflufolastat (18F) PET/CT scan will be performed in countries where it is approved.
Stereotactic Body Radiation Therapy (SBRT) will be administered to all metastatic Prostate Cancer (PC) lesions after randomization and before the start of treatment with AAA617 or observation.
- The duration of SBRT procedures is approximately 3 weeks.
- For participants randomized to the investigational arm (AAA617), the treatment duration will be up to 4 cycles of AAA617. For participants randomized to the control arm (observation) the treatment duration will end at the last fraction of SBRT administration.
- The visit frequency will be every week 1 and 3 of each of the 4 cycles and every 16 weeks thereafter (for both arms) until first event of disease progression (RECIST 1.1)
- The study duration is approximately 7.5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed prostate cancer prior to randomization
- •Participants must have biochemically recurrent disease after definitive treatment to prostate by Radical Prostatectomy ((RP), (alone or with post-operative radiation to prostate bed/pelvic nodes)) or External beam Radiation Therapy (EBRT), (prostate alone or prostate with seminal vesicle and/or pelvic nodes) and/or brachytherapy prior to randomization. Biochemical recurrence (BCR) is defined as: nadir PSA + 2 ng/mL post XRT (if participant received-radiation therapy to intact prostate) and PSA > 0.2 ng/mL and rising post RP (with or without post-operation Radiation Therapy (RT))
- •Participants must have OMPC with 1-5 PSMA -positive metastatic lesions on screening PSMA PET/CT scan (with either gallium (68Ga) gozetotide or piflufolastat (18F)) as visually assessed by BIRC. For definition of PSMA PET positivity, please refer to Section 8.1 and the Imaging Manual. Metastatic lesions may include regional/pelvic lymph nodes (N1), distant lymph nodes (M1a), bone (M1b), lung and others visceral (M1c) except liver and brain classified using American Joint Committee on Cancer (AJCC)
- •When counting the number of oligometastatic lesions, each lesion is counted as distinct metastasis irrespective of its anatomical location (e.g., one pelvic and one extra-pelvic lymph node will be counted as two metastatic lesions)
- •At least 1 PSMA-positive lesion must be a distant metastasis (M1) per AJCC8 classification at screening. For AJCC M staging, PSMA PET/CT information should be used
- •Participants must have a negative CI for M1 disease at screening.
- •For a participant not to be eligible, CI positive M1 lesions should be unequivocal in CI scans, i.e., potentially not attributable to findings thought to represent something other than tumor (e.g., degenerative, or post-traumatic changes or Paget's disease in bone lesions). For CI assessments, bone lesions must be assessed by bone scan only and soft tissue lesions must be assessed by CT/MRI scans only at screening.
- •Prior knowledge of PSMA PET positivity should not influence the radiologist (reader) in determination of CI positivity. Two different readers will be involved, one reader for PSMA PET/CT scan and one reader for CI: Reader will be blinded to PSMA PET scan results while reading CI scans. Reader should not modify their assessment of CI scans (e.g. changing a lesion previously identified as equivocal in CI to unequivocal) after reading the PSMA PET scan. Similarly, biopsy positivity should not influence the reader in the assessment of CI positivity. More details on the reading paradigm will be provided in the imaging charter
- •MRI for radiation treatment planning may show M1 disease but this will not exclude the participant from the study if the lesion is deemed negative per baseline CT or bone scans
- •Participants with pelvic disease (N1) seen in CI are allowed if the local spread is below common iliac bifurcation (per AJCC 8 definition of local disease)
- •Distant lymph node disease (M1a) that is visible per CI and less than 10mm in the short axis is not exclusionary irrespective of PSMA PET positivity.
- •If a previously surgically removed lesion was unequivocal for M1 by bone scan or CT, the participant is not eligible.
- •All metastatic lesions detected at screening must be amenable to SBRT
- •Non-castration testosterone level >100 ng/dL at screening
排除标准
- •Participants with de novo OMPC at screening
- •Unmanageable concurrent bladder outflow obstruction or urinary incontinence at screening. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed
- •Prior therapy with:
- •ADT (including bilateral orchiectomy) and ARPIs used for metastatic prostate cancer treatment
- •Participants who received AR-directed therapy, whether ADT or an ARPI or both, as neoadjuvant or adjuvant therapy as a component of their primary therapy, are eligible provided that they discontinued therapy ≥12 months prior to randomization for ADT (i.e., 12 months after the last day of the last injection) or ≥3 months if ARPI was given as monotherapy. ARPI's as a term includes both contemporary androgen synthesis inhibitors (e.g., abiraterone, galeterone, and orteneronel), and receptor inhibitors (enzalutamide, apalutamide and darolutamide).
- •Patients who biochemically relapsed after primary therapy may also have had treatment with AR directed therapy and participants who had SBRT with ADT are also eligible provided that the ARPI +/- ADT or ADT alone was terminated
- •≥12 months prior to randomization for ADT (i.e., 12 months after the last day of the last injection) or ≥3 months if ARPI was given as monotherapy.
- •Participants who received first generation anti-androgens (bicalutamide, flutamide, nilutamide, cyproterone) for biochemical recurrence or adjuvant/neoadjuvant therapy are eligible provided that they discontinued therapy ≥3 months prior to randomization.
- •Participants who have discontinued ADT due to disease progression are not eligible (i.e., Castration-Resistant Prostate Cancer (CRPC) participants)
- •Other hormonal therapy. e.g.,
- •Use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride), other steroidogenesis inhibitors (aminoglutethimide) if used in the context of prostate cancer treatment. Same medications are allowed if used for other indications: e.g., Benign Prostatic Hyperplasia (BPH), if stopped ≥3 months before randomization.
- •Radiopharmaceutical agents (e.g., Strontium-89, PSMA-targeted radioligand therapy)
- •Immunotherapy (e.g., sipuleucel-T)
- •Chemotherapy, except if administered in the adjuvant/neoadjuvant setting completed > 12 months before randomization
- •Any other investigational or systemic agents for metastatic disease
- •Radiation therapy external beam radiation therapy (EBRT) and brachytherapy within 28 days before randomization
- •Concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, hormonal therapy (see ADT initiation guidance in Section 6.8.2), Poly Adenosine Diphosphate-Ribose Polymerase (PARP) inhibitor, biological therapy or investigational therapy
- •Diagnosed at screening with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease/treatment free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer and superficial bladder cancer.
- •History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants participating in the study such as:
- •Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, and clinically significant second or third degree Atrioventricular (AV) block without a pacemaker
- •History of familial long QT syndrome or known family history of Torsades de Pointe
- •Participants in immediate need of ADT or other systemic therapy as assessed by the investigator. In addition, investigators should only enroll participants who are committed to delay castration in accordance with the scope of the study and are willing to wait to start systemic therapy until distant progression (MFS event) as assessed by CI (consisting with existing treatment guidelines) and confirmed by BIRC is reached. This must be discussed with the participants before ICF is signed.
- •Other protocol defined Inclusion/Exclusion may apply.
研究组 & 干预措施
Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617)
Experimental
All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for a planned 4 cycles.
干预措施: AAA617 (Drug)
Control arm: observation (watchful waiting)
No Intervention
All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by observation only.
Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617)
Experimental
All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for a planned 4 cycles.
干预措施: gallium (68Ga) gozetotide (25μg) (Drug)
Investigational Arm: lutetium (177Lu) vipivotide tetraxetan (AAA617)
Experimental
All participants will be treated with Stereotactic Body Radiation Therapy (SBRT) to all metastatic lesions followed by a dose of 7.4 GBq (200 mCi) +/- 10% of AAA617 which will be administered once every 6 weeks (1 cycle) for a planned 4 cycles.
干预措施: piflufolastat (18F) (Drug)
结局指标
主要结局
Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS)
时间窗: From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death due to any cause, whichever occurs first, assessed up to approximately 30 months
Blinded Independent Review Committee (BIRC) assessed Metastasis Free Survival (MFS) is defined as the time from randomization to first evidence of radiographically detectable bone or soft tissue distant metastasis by conventional imaging (i.e., Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) and bone scans) as assessed by BIRC using RECIST 1.1 or death due to any cause, whichever occurs first. Participants who are alive without distant metastasis at the analysis data cut-off or are lost to follow-up at the time of analysis will be censored for MFS at the time of their last adequate radiographic assessment. Clinical deterioration without objective radiographic evidence will not be considered as documented distant metastasis.
次要结局
- European Quality of Life (EuroQol) - 5 Domain 5 Level scale (EQ-5D- 5L)(From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months)
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)(From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months)
- Overall survival (OS)(From date of randomization until date of death from any cause, assessed up to approximately 74 months)
- Key secondary endpoint: Time to Hormonal Therapy (TTHT)(From date of randomization until date of Androgen Deprivation Therapy (ADT), assessed up to approximately 74 months)
- Time to next therapy (local or systemic)(From date of randomization until initiation of the next line of therapy (local or systemic), assessed up to approximately 74 months)
- Investigator assessed Metastasis Free Survival (MFS)(From date of randomization until first evidence of radiographically detectable bone or soft tissue distant metastasis or death from any cause, whichever occurs first, assessed up to approximately 74 months)
- Time to First Symptomatic Skeletal Event (TTSE)(From date of randomization till end of treatment (EOT) or death, whichever happens first, assessed up to approximately 74 months)
- Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire(From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months)
- Time to prostate specific antigen (PSA) progression (TTPSAP)(From date of randomization until date of first PSA progression, assessed up to approximately 74 months)
- Radiographic Progression Free Survival (rPFS)(From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 74 months)
- 24-month prostate-specific antigen (PSA) progression free survival (PFS)(From date of randomization until date of first documented PSA progression 2 or death from any cause, whichever occurs first, assessed up to approximately 74 months)
- Time to symptomatic progression(From date of randomization until date of first documented symptomatic progression, assessed up to approximately 74 months)
- Dose modifications and intensity for AAA617(From date of randomization until end of treatment (EOT), assessed up to approximately 30 months)
- Functional Assessment of Cancer Therapy - Radionuclide Therapy (FACT-RNT) Questionnaire(From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months)
- Brief Pain Inventory - Short Form (BPI-SF) Questionnaire(From date of randomization up till 42 day safety Follow-up, assessed up to approximately 74 months)
研究者
研究点 (192)
Loading locations...
相似试验
招募中
不适用
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate CancerMetastatic Castration Resistant Prostate CancerNCT06517719Novartis Pharmaceuticals500
招募中
3 期
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Advanced Gastroenteropancreatic Neuroendocrine TumorNCT05884255Jiangsu HengRui Medicine Co., Ltd.220
进行中（未招募）
2 期
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive TumoursNeuroendocrine CarcinomaNCT02236910Lawson Health Research Institute66
已完成
2 期
A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma.Non-Hodgkin's lymphomaLymfcancer10025322NL-OMON55476ordic Nanovector ASA1
进行中（未招募）
2 期
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCProstatic NeoplasmNCT05849298Novartis Pharmaceuticals49